Solvonis Therapeutics plc (LON:SVNS)
London · Delayed Price · Currency is GBP · Price in GBX 0.3300
+0.0250 (8.20%)
Aug 8, 2025, 4:29 PM BST
Solvonis Therapeutics Company Description
Solvonis Therapeutics plc, a clinical-stage biopharmaceutical company, develops novel medicines for addiction and mental health disorders.
The company develops SVN-001, an NMDA receptor antagonist that is in Phase III clinical trial for the treatment of severe alcohol use disorder; and SVN-002, which has completed Phase I clinical trial to treat moderate to severe alcohol use disorder.
Its pre-clinical stage product candidate includes SVN-SDN-14 for the treatment of post-traumatic stress disorder.
The company was formerly known as Graft Polymer (UK) Plc and changed its name to Solvonis Therapeutics plc in January 2025.
Solvonis Therapeutics plc was incorporated in 2017 and is headquartered in London, the United Kingdom.
Solvonis Therapeutics plc
| Country | United Kingdom |
| Founded | 2017 |
| Industry | Specialty Industrial Machinery |
| Sector | Industrials |
| Employees | 3 |
| CEO | Anthony Tennyson |
Contact Details
Address: Eccleston Yards London, SW1W 9NF United Kingdom | |
| Phone | 44 77 9543 0246 |
| Website | solvonis.com |
Stock Details
| Ticker Symbol | SVNS |
| Exchange | London Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | GBP |
| ISIN Number | GB00BMD1Z199 |
| SIC Code | 2821 |
Key Executives
| Name | Position |
|---|---|
| Anthony James Tennyson | Chief Executive Officer and Executive Director |
| Ryan Paul Neates | Finance Director |
| Prof. David John Nutt DM, FMedSci, FRCP, FRCPsych, FSB, Ph.D. | Chief Scientific Officer |